Pain and opioid addiction: What is the connection?

Current Pain and Headache Reports

Volumn 14, Issue 1, 2010, Pages 17-21

  Carinci, Adam J ^a   Mao, Jianren ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Aberrant drug related behavior (ADRB); Abuse; Addiction; Cellular mechanisms; Chronic pain; Epidemiology; Neurobiology; Opioids

Indexed keywords

NARCOTIC ANALGESIC AGENT;

BEHAVIOR DISORDER; CELL ACTIVATION; CHRONIC PAIN; DISEASE ASSOCIATION; GLIA CELL; HUMAN; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; PATIENT ASSESSMENT; PATIENT MONITORING; PRESCRIPTION; RISK ASSESSMENT; SEX DIFFERENCE; SHORT SURVEY; SUBSTANCE ABUSE;

ANALGESICS, OPIOID; CHRONIC DISEASE; HUMANS; OPIOID-RELATED DISORDERS; PAIN;

EID: 77649190269     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-009-0086-x     Document Type: Short Survey

References (40)

1. Stewart WF, Ricci JA, Chee E, et al.: Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003, 290:2443-2454.
2. Verhaak PF, Kerssens JJ, Dekker J, et al.: Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998, 77:231-239.
3. Martin BI, Deyo RA, Mirza SK, et al.: Expenditures and health tatus among adults with back and neck problems. JAMA 2008, 299:656-664. (Published erratum appears in JAMA 2008, 299:2630.)
4. Patt RB, Burton AW: Pain associated with advanced malignancy, including adjuvant analgesic drugs in cancer pain management. In Evaluation and Treatment of Chronic Pain. Edited by Argoff GM. New York: Lippincott, Williams and Wilkins; 1998:337-376.
5. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E: Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006, 174:1589-1594.
6. Kalso E, Edwards JE, Moore RA, McQuay HJ: Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004, 112:372-380.
7. Manchikanti L: Health care reform in the United States: radical surgery needed now more than ever. Pain Physician 2008, 11:13-42.
8. Ballantyne JC, LaForge KS: Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007, 129:235-255. (Published erratum appears in Pain 2007, 131:350.)
9. Ballantyne JC, Mao J: Opioid therapy for chronic pain. N Engl J Med 2003, 349:1943-1953.
10. Mao J: Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 2002, 100:213-217.
11. Fishbain DA, Cole B, Lewis J, et al.: What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drugrelated behaviors? A structured evidence-based review. Pain Med 2008, 9:444-459. This important review indicates that chronic opioid therapy will lead to abuse/addiction in a very small percentage of patients.
12. Back SE, Payne RA, Waldrop AE, et al.: Prescription opioid aberrant behaviors: a pilot study of sex differences. Clin J Pain 2009, 25:477-484.
13. Turk DC, Swanson KS, Gatchel RJ: Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008, 24:497-508.
14. Sproule B, Brands B, Li S, Catz-Biro L: Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. Can Fam Physician 2009, 55:68-69.e1-5
15. Rosenblum A, Marsch LA, Joseph H, Portenoy RK: Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008, 16:405-416.
16. Ferrell BR, McCaffery M, Rhiner M: Pain and addiction: an urgent need for change in nursing education. J Pain Symptom Manage 1992, 7:117-124.
17. Fishbain DA, Rosomoff HL, Rosomoff RS: Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain 1992, 8:77-85.
18. Hoffmann NG, Olofsson O, Salen B, Wickstrom L: Prevalence of abuse and dependency in chronic pain patients. Int J Addict 1995, 30:919-927.
19. Katz NP, Sherburne S, Beach M, et al.: Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003, 97:1097-1102.
20. Passik SD, Kirsh KL, Whitcomb L, et al.: A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004, 26:552-561.
21. DeLeo JA, Colburn RW, Nichols M, Malhotra A: Interleukin-6- mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996, 16:695-700.
22. Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
23. Song P, Zhao ZQ: The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001, 39:281-286.
24. Cui Y, Chen Y, Zhi JL, et al.: Activation of p38 mitogen-activated protein kinase in spinal microglia mediates morphine antinociceptive tolerance. Brain Res 2006, 1069:235-243.
25. Alonso E, Garrido E, Diez-Fernandez C, et al.: Yohimbine prevents morphine-induced changes of glial fibrillary acidic protein in brainstem and alpha2-adrenoceptor gene expression in hippocampus. Neurosci Lett 2007, 412:163-167.
26. Narita M, Kuzumaki N, Narita M, et al.: Chronic pain-induced emotional dysfunction is associated with astrogliosis due to cortical delta-opioid receptor dysfunction. J Neurochem 2006, 97:1369-1378.
27. Herber DL, Maloney JL, Roth LM, et al.: Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia 2006, 53:382-391.
28. Tawfik VL, LaCroix-Fralish ML, Nutile-McMenemy N, DeLeo JA: Transcriptional and translational regulation of glial activation by morphine in a rodent model of neuropathic pain. J Pharmacol Exp Ther 2005, 313:1239-1247.
29. Yang YL, Lu KT: Facilitation of conditioned fear extinction by cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novoprotein synthesis in basolateral nucleus of amygdala. Neuroscience 2005, 134:247-260.
30. Lu L, Hope BT, Dempsey J, et al.: Central amygdala ERK signaling pathway is critical to incubation of cocaine craving. Nat Neurosci 2005, 8:212-219.
31. Valjent E, Corbille AG, Bertran-Gonzalez J, et al.: Inhibition of ERK pathway or protein synthesis during reexposure to drugs of abuse erases previously learned place preference. Proc Natl Acad Sci U S A 2006, 103:2932-2937.
32. Asensio VJ, Miralles A, Garcia-Sevilla JA: Stimulation of mitogen-activated protein kinase kinases (MEK1/2) by mu-, delta- and kappa-opioid receptor agonists in the rat brain: regulation by chronic morphine and opioid withdrawal. Eur J Pharmacol 2006, 539:49-56.
33. Tomlinson GS, Simmonds P, Busuttil A, et al.: Upregulation of microglia in drug users with and without pre-symptomatic HIV infection. Neuropathol Appl Neurobiol 1999, 25:369-379.
34. Hauser KF, El Hage N, Buch S, et al.: Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res 2005, 8:63-80.
35. Hauser KF, El Hage N, Stiene-Martin A, et al.: HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 2007, 100:567-586.
36. Bowers MS, Kalivas PW: Forebrain astroglial plasticity is induced following withdrawal from repeated cocaine administration. Eur J Neurosci 2003, 17:1273-1278.
37. Festa ED, Cecala C, Quinones-Jenab V, Jenab S: Cocaine modulates mu-opioid receptor mRNA but not c-fos mRNA levels in primary cortical astrocytes. Brain Res Bull 2002, 58:285-288.
38. Hutchinson MR, Bland ST, Johnson KW, et al.: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 2007, 7:98-111.
39. Passik SD: Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009, 84:593-601.
40. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130. The 2009 guidelines address important concepts in risk assessment, prescribing, and monitoring of opioid medications